Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (DE:CN2)
FRANKFURT:CN2
Holding DE:CN2?
Track your performance easily
CN2 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€10.93 - €18.83
Previous Close€18
Volume0.00
Average Volume (3M)96.00
Market Cap
€2.13B
Enterprise Value€1.80B
Total Cash (Recent Filing)$375.69M
Total Debt (Recent Filing)$2.99M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 06, 2024EPS Estimate
€0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding118,687,897
10 Day Avg. Volume2
30 Day Avg. Volume96
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.51
Price to Sales (P/S)5.60
Price to Cash Flow (P/CF)9.50
P/FCF Ratio9.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.13
Enterprise Value/Gross Profit5.19
Enterprise Value/Ebitda13.35
Forecast
1Y Price Target
€26.93Price Target Upside49.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Catalyst Pharma News
Options Prices
Currently, No data available
---
Ownership Overview
13.53% Insiders
18.74% Mutual Funds
48.47% Other Institutional Investors
19.26% Public Companies and
Individual Investors
CN2 FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was €10.93 and its highest was €18.82 in the past 12 months.
What is Catalyst Pharma’s market cap?
Currently, no data Available
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is Nov 06, 2024 which is in 41 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Aug 07, 2024. The company reported €0.297 earnings per share for the quarter, beating the consensus estimate of €0.205 by €0.092.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is €0.27.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 118,687,900 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of €0.297 in its last earnings report, beating expectations of €0.205. Following the earnings report the stock price went up 5.197%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Among the largest hedge funds holding Catalyst Pharma’s share is Deerfield Management Company, LP. It holds Catalyst Pharma’s shares valued at 141M.
---
Catalyst Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€26.93 (49.66% Upside)
€26.93 (49.66% Upside)
Blogger Sentiment
Bullish
DE:CN2 Sentiment 88%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $5.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.88%
12-Months-Change
Fundamentals
Return on Equity
13.85%
Trailing 12-Months
Asset Growth
59.13%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.
---
CN2 Earnings Call
Q2 2024
0:00 / 0:00
---
CN2 Stock 12 Month Forecast
Average Price Target
€26.93
▲(49.66% Upside)
Technical Analysis
Catalyst Pharma
―
ACADIA Pharmaceuticals
―
ANI Pharmaceuticals
―
BioCryst
―
PTC Therapeutics
―
Best Analysts Covering CN2
1 Year
1 Year Success Rate
18/21 ratings generated profit
1 Year Average Return
+50.11%
assigned a buy rating 2 months ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +50.11% per trade.
---